LD-2 disclosure · 2nd Quarter - Report
LUNDBECK PHARMACEUTICALS LLC
Client
- Description
- Specialty and Central Nervous System Bio-pharmaceutical manufacturing.
- Location
- Illinois · United States of America
Registrant
- Description
- Government affairs.
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
2 issuesHealth Issues
Issues regarding Pill Penalty caused by the Inflation Reduction Act (IRA) P.L. No: 117-169, drug pricing, and efforts to create a Neuroscience Center of Excellence at FDA.
LobbyistsSHANNON FINLEY · LUKE HATZIS · ANN JABLON · JOSEPH EANNELLO · JEFFREY CARROLL · JOHN MARTIN · KAREN STONE · mr CHARLES PATRICK MICHAELS
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medicare/Medicaid
Issues regarding the Inflation Reduction Act (IRA) P.L. No: 117-169, drug pricing, and efforts to create a Neuroscience Center of Excellence at FDA. Issues regarding effective solutions for improving clinical care in long-term care settings and other solutions aimed at improving the diagnosis and management of neuropsychiatric symptoms (NPS) in dementia. Orphan Drug Provisions included in HR.1, the One Big Beautiful Bill Act (OBBB) P.L. 119-21. 340 program issues.
LobbyistsSHANNON FINLEY · LUKE HATZIS · ANN JABLON · JOSEPH EANNELLO · JEFFREY CARROLL · JOHN MARTIN · KAREN STONE · mr CHARLES PATRICK MICHAELS
TargetedSENATE · HOUSE OF REPRESENTATIVES